0001209191-17-054440.txt : 20170929 0001209191-17-054440.hdr.sgml : 20170929 20170929174802 ACCESSION NUMBER: 0001209191-17-054440 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20170927 FILED AS OF DATE: 20170929 DATE AS OF CHANGE: 20170929 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Nagler David CENTRAL INDEX KEY: 0001416175 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37833 FILM NUMBER: 171112601 MAIL ADDRESS: STREET 1: ARYX THERAPEUTICS,INC. STREET 2: 6300 DUMBARTON CIRCLE CITY: FREMONT STATE: CA ZIP: 94555 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Audentes Therapeutics, Inc. CENTRAL INDEX KEY: 0001628738 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 461606174 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 600 CALIFORNIA ST., 17TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94108 BUSINESS PHONE: 415-638-6556 MAIL ADDRESS: STREET 1: 600 CALIFORNIA ST., 17TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94108 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-09-27 0 0001628738 Audentes Therapeutics, Inc. BOLD 0001416175 Nagler David C/O AUDENTES THERAPEUTICS, INC. 600 CALIFORNIA STREET, 17TH FLOOR SAN FRANCISCO CA 94108 0 1 0 0 SVP, HR & Corp. Affairs Common Stock 2017-09-27 4 M 0 3750 2.1852 A 3750 D Common Stock 2017-09-27 4 S 0 3750 30.00 D 0 D Stock Option (right to buy) 2.1852 2017-09-27 4 M 0 3750 0.00 D 2025-02-04 Common Stock 3750 37347 D This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person. The option vested as to 25% of the total shares on February 1, 2016, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 1, 2019, subject to the reporting person's provision of service to the issuer on each vesting date. /s/ Thomas Soloway as attorney-in-fact for David Nagler 2017-09-27